Factors associated with response to acetylcholinesterase inhibition in dementia: A cohort study from a secondary mental health care case register in London

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Perera, Gayan ^a   Khondoker, Mizanur ^a   Broadbent, Matthew ^b   Breen, Gerome ^a   Stewart, Robert ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; NEUROLEPTIC AGENT; RIVASTIGMINE;

AGED; ARTICLE; CHOLINESTERASE INHIBITION; COGNITION; COHORT ANALYSIS; DEMENTIA; DRUG RESPONSE; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MULTIINFARCT DEMENTIA; OBSERVATIONAL STUDY; RETROSPECTIVE STUDY; TREATMENT OUTCOME; UNITED KINGDOM; VERY ELDERLY; COMPARATIVE STUDY; DRUG EFFECTS; MIDDLE AGED; PSYCHOLOGY; REGISTER;

AGED; AGED, 80 AND OVER; CHOLINESTERASE INHIBITORS; COGNITION; DEMENTIA; FEMALE; HUMANS; LONDON; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; REGISTRIES; RETROSPECTIVE STUDIES;

EID: 84913553634     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0109484     Document Type: Article

References (27)

1. Birks J, Harvey RJ (2006) Donepezil for dementia due to Alzheimer's disease. Cochrane Database of Systematic Reviews, 25;(1): CD001190.
2. Inoue J, Hoshino R, Nojima H, Ishida W, Okamoto N (2010) Investigation of responders and non-responders to long-term donepezil treatment. Psychogeriatrics, 10(2): 53-61.
3. Santoro A, Siviero P, Minicuci N, Bellavista E, Mishto M, et al. (2010) Effects of Donepezil, Galantamine and Rivastigmine in 938 Italian Patients with Alzheimer's Disease A Prospective, Observational Study. CNS Drugs, 24(2): 163-76.
4. Stewart R, Soremekun M, Perera G, Broadbent M, Callard F, et al. (2009) The South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLAM BRC) case register: development and descriptive data. BMC Psychiatry, 12; 9: 51.
5. Hayes RD, Chang C-K, Fernandes A, Broadbent M, Lee W, et al (2011). Associations between substance use disorder sub-groups, life expectancy and allcause mortality in a large British specialist mental healthcare service. Drug and Alcohol Dependence. 118, 56-61.
6. Chang C-K, Hayes RD, Perera G, Broadbent MTM, Fernandes AC, et al. (2010) Life expectancy at birth for people with serious mental illness from a secondary mental health care case register in London, UK PloS ONE 6(5).
7. Folstein MF, Folstein SE, McHugh PR (1975) Mini-Mental State: A practical method for grading the cognitive state of patients for clinicians. Journal of Psychiatric Research, 12: 189-98.
8. Rigby RA, Stasinopoulos DM (2005) Generalized additive models for location, scale and shape. Applied Statistics, 54(3); 507-54.
9. Putt R, Dineen C, Janes D, Series H, McShane R (2006) Effectiveness of acetylcholinesterase inhibitors: diagnosis and severity as predictors of response in routine practice. International Journal of Geriatric Psychiatry, 21(8): 755-60.
10. Molinuevo JL, Berthier ML, Rami L (2011) Donepezil provides greater benefits in mild compared to moderate Alzheimer's disease: implications for early diagnosis and treatment. Archives of Gerontology & Geriatrics, 52(1): 18-22.
11. Wallin AK, Andreasen N, Eriksson S, Batsman S, Nasman B, et al. (2007) Donepezil in Alzheimer's disease: What to expect after 3 years of treatment in a routine clinical setting. Dementia and geriatric cognitive disorders, 23(6): 150- 60.
12. Lopez-Pousa S, Olmo JG, Franch JV, Estrada AT, Cors OS, et al. (2006) Comparative analysis of mortality in patients with Alzheimer's disease treated with donepezil or galantamine. Age & Ageing, 35(4): 365-71.
13. Lopez OL, Schwam E, Cummings J, Gauthier S, Jones R, et al. (2010) Predicting cognitive decline in Alzheimer's disease: An integrated analysis. Alzheimer's Dementia, 6(6): 431-9.
14. Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson PH, et al. (1978) Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. British Medical Journal, 2(6150): 1457-9.
15. Wallin A, Andreasen N, Eriksson S, Wattmo C, Minthon L (2005) Analysis of the heterogeneity in treatment response to donepezil in Alzheimer's disease; conclusions from the Swedish Alzheimer Treatment Study Group P2:111. International Psychogeriatrics, 17 (Suppl. 2): 315.
16. Neary D, Snowden JS, Mann DM, Bowen DM, Sims NR, et al. (1986) Alzheimer's disease: A correlative study. J Neurol Neurosurg Psychiatry 1986; 49:229-237.
17. Adelman S, Blanchard M, Rait G, Leavey G, Livingston G (2011) Prevalence of dementia in African-Caribbean compared with UK-born White older people: Two-stage cross-sectional study. British Journal of Psychiatry, 199(2): 119-25.
18. Bowler JV, Munoz DG, Merskey H, Hachinski V (1998) Factors affecting the age of onset and rate of progression of Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 65(2): 184-90.
19. Musicco MI, Palmer K, Salamone G, Lupo F, Perri R, et al. (2009) Predictors of progression of cognitive decline in Alzheimer's disease: The role of vascular and sociodemographic factors. Journal of Neurology, 256(8): 1288-95.
20. Moretti A, Gorini A, Villa RF (2011) Pharmacotherapy and prevention of vascular dementia. CNS Neurol Disord Drug Targets 2011; 10(3): 370-90.
21. Irizarry MC, Webb DJ, Bains C, Barrett SJ, Lai RY, et al. (2008) Predictors of placebo group decline in the Alzheimer's disease Assessment Scale-cognitive subscale (ADAS-Cog) in 24 week clinical trials of Alzheimer's disease. Journal of Alzheimer's Disease, 14(3): 301-11.
22. Herrmann N, Lanctot KL (2005) Do atypical antipsychotics cause stroke? CNS Drugs, 19(2): 105-23.
23. Wallin AK, Gustafson L, Sjogren M, Wattmo C, Minthon L (2004) Five-Year Outcome of Cholinergic Treatment of Alzheimer's Disease: Early Response Predicts Prolonged Time until Nursing Home Placement, but Does Not Alter Life Expectancy. Dementia & Geriatric Cognitive Disorders, 18(2): 197-206.
24. Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, et al. (2001) A 1- year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology, 57(3): 489-95.
25. Rogers SL, Doody RS, Pratt RD, Ieni JR (2000) Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. European Neuropsychopharmacology, 10(3): 195- 203.
26. Crane PK, Narasimhalu K, Gibbons LE, Mungas DM, Haneuse S, et al. (2008) Item response theory facilitated cocalibrating cognitive tests and reduced bias in estimated rates of decline. J Clin Epidemiol. 61(10): 1018-27.
27. Proust-Lima CI, Dartigues JF, Jacqmin-Gadda H (2011) Misuse of the linear mixed model when evaluating risk factors of cognitive decline. Am J Epidemiol.174(9): 1077-88.